glp-1 and sibo Will Gut Microbiota Help Design the Next Generation of GLP-1-Based Therapies for Type 2 Diabetes? Glucagon-like peptide-1 receptor: mechanisms and

Injectable/IV NAD+ is not FDA-approved (or approved by any major regulator) for energy, metabolic or longevity uses, and its safety and efficacy for these uses are not established presented for research and educational use only

The previous Hims subscription required a 6-month commitment, so the new monthly cadence gives you a lower-cost way to try the membership

The 80mg formulation is suited to research environments requiring a multi-peptide system for controlled experimental use

So at least in that regard, if patients are obtaining drug from a pharmacy that has a reputation for quality products, I feel a little more comfortable, but as you mentioned, the regulation is not as robust, if you will.